PerkinElmer, Inc.

686 articles with PerkinElmer, Inc.

• PerkinElmer Announces Redemption of 5% Senior Unsecured Notes Due in 2021

  9/13/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it is giving notice of the redemption of all of its outstanding 5% Senior Unsecured Notes due in 2021 (the “2021 Notes”).

• PerkinElmer Prices Offering of Senior Notes

  9/10/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, announced today that it has priced an offering of $850 million aggregate principal amount of 3.300% Senior Notes due 2029 at an issue price of 99.670% of the principal amount.

• Clinical Study Published in Prenatal Diagnosis Further Validates PerkinElmer’s Vanadis Fully Automated NIPT Platform

  8/21/2019

  CE-Marked Solution Gives Pregnant Women Widespread Access to Non-Invasive Prenatal Testing

• PerkinElmer Announces Leadership Succession Plan

  8/21/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that after a career of more than 20 years at the Company, including the last 12 years as chief executive officer, Robert F. Friel, has decided to retire as chairman and CEO and member of the board of directors as of the end of the Company’s fiscal year on December 29, 2019.

• PerkinElmer Launches EUROIMMUN ELISA for Detection of Aspergillus Infections

  8/5/2019

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of the new EUROIMMUN Aspergillus Antigen ELISA.

• PerkinElmer Announces Financial Results for the Second Quarter of 2019

  7/29/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended June 30, 2019.

• PerkinElmer Board Declares Quarterly Dividend payable on November 8, 2019

  7/25/2019

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on July 25, 2019.

• PerkinElmer and EverlyWell Announce Collaboration to Expand U.S. At-Home Health Test Market

  7/24/2019

  Combines PerkinElmer’s expertise in immunodiagnostic testing and state-of-the-art genomics program with EverlyWell’s consumer health offerings

• PerkinElmer to Hold Earnings Call on Monday, July 29, 2019

  7/8/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Monday, July 29, 2019, after market close, the Company will release second quarter 2019 results.

• FDNA and PerkinElmer Announce Collaboration to Offer Enhanced Genetic Testing Augmented by AI and Facial Analysis

  6/25/2019

  Together, they will offer genomic services paired with next-generation phenotyping technologies for more efficient and accurate diagnoses.

• PerkinElmer to Present at Goldman Sachs Global Healthcare Conference - May 29, 2019

  5/29/2019

  PerkinElmer, Inc. announced that the Company will present at the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019, at 2:40 p.m. PT in Rancho Palos Verdes, California.

• PerkinElmer Board Declares Quarterly Dividend - April 25, 2019

  4/25/2019

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on April 25, 2019.

• PerkinElmer Announces Financial Results for the First Quarter of 2019

  4/25/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended March 31, 2019.

• PerkinElmer Joins Accenture’s Life Sciences Ecosystem to Help Drive Innovation in Drug Discovery and Scientific Research

  4/16/2019

  Announcement at 2019 Bio-IT World Conference & Expo syncs with PerkinElmer’s strategy to get labs from big data overload to research insights faster and easier

• PerkinElmer to Hold Earnings Call on Thursday, April 25, 2019

  4/11/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that on Thursday, April 25, 2019, after market close, the Company will release first quarter 2019 results.

• PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive Health Management

  4/2/2019

  Available in Helix’s DNA marketplace, GenePrism: Actionable Insights is the first clinical-grade DNA test available to health individuals that analyzes all 59 medically actionable genes identified by the American College of Medical Genetics and Genomics

• PerkinElmer to Present at Cowen and Company 39th Annual Health Care Conference

  2/22/2019

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the Company will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019, at 1:30 p.m. ET at the Marriott Copley Place in Boston.

• PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year 2018

  1/31/2019

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended December 30, 2018.

• PerkinElmer Board Declares Quarterly Dividend on January 24, 2019

  1/24/2019

  The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on January 24, 2019.

• PerkinElmer to Hold Earnings Call on Thursday, January 31, 2019

  1/4/2019

  PerkinElmer, Inc. announced that on Thursday, January 31, 2019, after market close, the Company will release fourth quarter 2018 results